Dr. Grunig's laboratory is developing a new drug for asthma.  This research is through a collaboration with Mercia Pharmaceuticals and funded by the NIH through the small business program (top scored STTR / R41 grant).

Mercia’s therapeutic vaccine will simultaneously immunize patients against multiple targets involved in the disease. The lead targets are immune system messengers which are integral to the allergic and asthmatic response. By active immunization, the body’s own immune system is recruited to simultaneously control the levels of these messengers for prolonged periods. Immunization against these targets represents a novel therapeutic approach for the treatment of asthma and other allergic conditions. In this way the severity of the allergic and asthmatic symptoms will be ameliorated and the reliance on medications such as steroids, with their significant side effects, will be reduced.